Aims: It is known that there is a relationship between diabetic complications and chronic inflammation characterized by alterations in circulating acute phase proteins. It has been emphasized that inflammation contributes to diabetic complications and that gliclazide -an antidiabetic sulfonylurea decreases the development of such complications. In this study, we aimed to investigate whether gli...

BACKGROUND Several observational studies were conducted with vildagliptin in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan, showing significantly lower incidences of hypoglycemia with vildagliptin versus sulfonylureas, including gliclazide. It was of interest to complement the existing real-life evidence with data from a randomized, double-blind, clinical trial. CLINICA...

Starting off with a structure derived from the natural compound multiflorine, a derivatisation program aimed at the discovery and initial characterisation of novel compounds with antidiabetic potential. Design and discovery of the structures was guided by oral bioactivities obtained in oral glucose tolerance tests in mice. 55P0110, one among several new compounds with distinct anti-hyperglycaem...

BACKGROUND The combination of metformin and a sulphonylurea has been recommended for treatment of type 2 diabetes. A, scored, breakable, extended release, once daily fixed dose combination (FDC) of gliclazide and metformin is available in India. OBJECTIVE To assess the initial blood glucose lowering efficacy, glycemic control and patient acceptability of the fixed dose combination of original...

Since the introduction of gliclazide in the pharmaceutical industry, a large number of research groups have been engaged in various investigations aiming to enhance its biomedical application. But, very limited efforts have been made to study polymorphism of gliclazide. Therefore, this study focuses on solvent-induced polymorphism of gliclazide and its characterization by thermal methods. Three...

Formulation of gliclazide in the form of extendedrelease tablet in 30 and 60 mg dosage forms was performed using hypromellose (HPMC K4M) as a retarding agent. Drug-release profiles were investigated in comparison with references Diamicron MR 30 and 60 mg tablets. The effect of size of powder particles, the amount of hypromellose in formulation, hardness of tablets, and also the effect of halvin...

The objective of the study was to compare pharmacokinetic and pharmacodynamic parameters of gliclazide after administration of immediate (IR) and modified release (MR) tablets. The experiment included rats with both normoglycemia and streptozocin (STZ)-induced hyperglycemia. Several MR formulations were designed and in-vitro drug release profile was assessed by a dissolution test. For the furth...

1. Sulphonylurea derivatives are commonly used in the treatment of non-insulin-dependent diabetes mellitus. It is, however, unclear whether the hypoglycaemic effect of sulphonylurea derivatives is additive to the effect of glucose, or whether sulphonylurea derivatives act by increasing B-cell glucose sensitivity. 2. We assessed the effect of gliclazide on glucose-stimulated insulin secretion in...

The objective of this study was to investigate the effect of oral administration of antiretroviral drugs (indinavir, ritonavir, atazanavir, efavirenz and nevirapine) on the pharmacodynamics of gliclazide in rats (normal and diabetic) and rabbits with respect to glucose-insulin homeostasis to evaluate the safety and effectiveness of the combinations. Blood samples were collected at regular time ...

glycemic agents belonging to biguanide group and secondgeneration sulphonyl urea respectively. Generally, they are individually used in the treatment of type II non-insulin dependent diabetes mellitus. The combination of both the drugs are also available and it is reported to be effective than individual therapy. Metformin acts by decreasing hepatic glucose production and improves insulin sensi...